Drugs A - Z

ticlopidine Images

Generic Name: ticlopidine

Brand Names: Ticlopidine Hydrochloride, Ticlid

There is an FDA Alert for this drug. Click here to view it.

  • Possible life-threatening adverse hematologic effects (e.g., neutropenia and/or agranulocytosis, thrombotic thrombocytopenic purpura [TTP], aplastic anemia).
  • Neutropenia occurred in 2.4% of stroke patients in clinical trials; TTP and aplastic anemia reported rarely.
  • Incidence of neutropenia, TTP, or aplastic anemia peaks about 4–6, 3–4, or 4–8 weeks, respectively, following initiation of therapy and declines thereafter. Adverse hematologic effects occur infrequently >3 months after initiation of therapy.
  • Risk factors for development of adverse hematologic effects not identified.
  • Careful clinical and hematologic monitoring required, especially during the first 3 months of therapy. Discontinue therapy immediately if adverse hematologic effects occur. (See Hematologic Toxicity under Cautions.)

The Healthline Site, its content, such as text, graphics, images, search results, and other material contained on the Healthline Site ("Content"), its services, and any information or material posted on the Healthline Site by third parties are provided for informational purposes only. None of the foregoing is a substitute for professional medical advice, examination, diagnosis, or treatment. Always seek the advice of a physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on the Healthline Site. If you think you may have a medical emergency, call your doctor or 911 immediately. Please read the Terms of Service for more information regarding use of the Healthline Site.